ARTES Biotechnology issued New Patent in Australia for VLP Technology

(PresseBox) (Langenfeld, ) ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce the issuance of a new patent for their VLP platform. The patent will further strengthen the Metavax® platform of the company. In combination with the expression platform Hansenula Metavax® is a unique tool for the development of affordable, safe and effective vaccines.
“Our intellectual property strategy is to provide multiple layers of protection for our technology platform portfolio. We believe that this new patent will have additional reinforcement to our existing patent estate and for our service we offer clients for vaccine development,” said Dr. Melanie Piontek, Business Development Director of ARTES.

Kontakt

ARTES Biotechnology GmbH
Elisabeth-Selbert-Str. 9
D-40764 Langenfeld
Dr. Melanie Piontek
Business Development Director
Social Media